Main uses of Selexid

Selexid is an antibiotic that contains the active substance pivmecillinam. It belongs to a group of medicines known as penicillins, specifically the amidinopenicillins. Its primary function is to treat bacterial infections by interfering with the development of the bacterial cell wall, leading to the destruction of the bacteria causing the illness.

Primary indications

This medication is primarily used for the treatment of urinary tract infections (UTIs). Because of its specific mechanism of action, it is often effective against common bacteria that reside in the digestive tract and enter the urinary system.

• Acute uncomplicated cystitis: This is a sudden infection of the bladder, often referred to as a lower urinary tract infection. It is common in women and typically presents with symptoms such as a frequent urge to urinate or a stinging sensation during urination.
• Chronic or recurrent bacteriuria: In some cases, Selexid is used to manage long-term or repeating instances where bacteria are present in the urine, even if symptoms are not always severe.
• Salmonellosis: While less common, this antibiotic may be used for the treatment of certain types of infections caused by Salmonella bacteria, particularly when the infection involves the systemic circulation or requires specific targeting of the gastrointestinal pathogens.

Benefits and clinical efficacy

Selexid offers several benefits for patients dealing with susceptible bacterial infections:

• Targeted action: Unlike broad-spectrum antibiotics that affect a wide range of bacteria throughout the body, pivmecillinam has a high degree of specificity for the Gram-negative bacteria that most frequently cause urinary tract infections, such as Escherichia coli.
• Preservation of healthy flora: Due to its targeted nature, it tends to have a lower impact on the natural, beneficial bacteria living in the gut and vagina compared to other more general antibiotics. This can reduce the likelihood of secondary issues like yeast infections or significant digestive upset.
• Low resistance rates: Many common urinary pathogens remain highly sensitive to this medication, making it a reliable choice for first-line treatment when other antibiotics might face bacterial resistance.

Eligibility and Contraindications for Selexid (Pivmecillinam)

Official regulatory documents define specific populations who can and cannot use Selexid based on allergy, genetic risks, and certain physiological states.

Interactions with other medicines and products

This section summarizes officially documented interactions for Selexid (pivmecillinam), based strictly on regulatory data.

Formal Contraindications and Avoidance

Certain combinations are advised to be avoided due to increased safety risks. Concurrent treatment with valproic acid, divalproex sodium, or other pivalate-generating drugs is restricted as it significantly increases the risk of carnitine depletion.

Pharmacokinetic and Pharmacodynamic Interactions

Other Interaction Considerations

Regulatory documentation notes that the absorption of pivmecillinam is practically unaffected by food. Specific caution is documented for patients with impaired renal function, as they may experience raised mecillinam blood levels if repeated doses are given due to reduced excretion.

Selexid is the oral prodrug pivmecillinam . Following absorption from the gastrointestinal tract, non-specific esterase enzymes present in the blood, intestinal mucosa, and other tissues catalyze the hydrolysis of pivmecillinam to release the active compound, mecillinam (also known as amdinocillin). Mecillinam belongs to the beta-lactam class of antibiotics. Its primary biological target is the Penicillin-Binding Protein 2 (PBP 2), which is located on the inner membrane of the bacterial cell wall, particularly in Gram-negative bacteria. Mecillinam acts as an inhibitor by forming a stable, covalent bond with PBP 2, a transpeptidase enzyme critical for the final stages of peptidoglycan synthesis. PBP 2 is responsible for initiating the elongation of peptidoglycan chains. This molecular interaction prevents the proper cross-linking of peptidoglycan monomers, interfering with the formation of a rigid, stable bacterial cell wall. The downstream cascade involves the osmotic instability of the bacterial cell. This system-level physiological consequence results in the weakening of the cell wall structure and subsequent cell lysis.

The administration of Selexid (pivmecillinam) is strictly by the oral route using film-coated tablets. Established instructions for use establish a defined schedule and specific intake conditions to ensure proper administration.

Official Dosing and Frequency

The standard adult dosing schedule for the primary indication—uncomplicated cystitis—requires the medicine to be taken three times a day (TID). Dosing recommendations vary by region and approved strength:

• A typical regimen is one 185 mg tablet TID for 3 to 7 days.
• Other regimens involve 200 mg or 400 mg strengths, also taken three times daily, with specific courses lasting as short as 3 days. Total daily doses may reach 1.2 – 2.4 g for other approved indications, such as treating the Salmonella carrier state.

Administration Conditions

The tablets must be swallowed whole without crushing or chewing and must be taken with at least half a glass of fluid or liquid to facilitate proper transit. The medicine may be taken with or without food, although instructions may specify taking it with or immediately after a meal.

Procedural and Population Rules

For a missed dose, the procedural instruction is to take the dose as soon as remembered, but the subsequent dose must not be doubled to compensate. The treatment course, which is typically short (3 to 7 days), must be completed as prescribed. No dosage adjustment is generally necessary for older adults or in cases of mild renal or hepatic impairment, simplifying the overall use protocol.

Research evidence / Overview of studies

Study Population and Design

Research has explored the compound's activity in pathways involving key inflammatory mediators. Studies have evaluated whether the substance may influence symptoms associated with chronic arthritis.

The majority of clinical trials were randomized, double-blind, and placebo-controlled and enrolled participants diagnosed with moderate to severe rheumatoid arthritis (RA) or psoriatic arthritis (PsA). Trial durations ranged from 12 weeks to one year. Consultation with a healthcare provider is generally required before making changes to any existing medication.

Key Efficacy Findings

Chronic Arthritis (RA and PsA)

Studies assessed the effect on the frequency of flare-ups. The primary endpoint in most trials was the American College of Rheumatology (ACR) response criteria, which measures the percentage reduction in tender and swollen joint counts.

• In trials focused on RA, a difference in the rate of achieving an ACR20 response was noted between participants assigned the compound and those on placebo.
• In studies on PsA, the trials reported changes in swelling, and some studies have compared the effects of the compound to others in the same class.

Studies investigated whether the compound influenced joint mobility. Research examined the onset and duration of effects related to acute pain. Findings related to the prevention of long-term joint damage remain limited and require further investigation.

Safety and Tolerability Profile

The compound's tolerability profile in trials was characterized by generally manageable adverse event reporting. Common side effects reported included mild gastrointestinal upset and headache. Trials have evaluated the long-term tolerability and safety profile in adult participants. Serious adverse events were infrequent but included reports of elevated liver enzymes and a small number of serious infections.

In clinical trials, the compound was typically administered with food. The potential for the compound to interact significantly with other medications necessitated a full review of participants’ concurrent drug use by investigators.

Key Studies & References Clinical Trials | XELJANZ® (tofacitinib) For PsA | Safety Info

How to Store and Dispose of Selexid?

Official Storage Conditions

Selexid (pivmecillinam hydrochloride) tablets must be stored at a temperature below 25 C or at controlled room temperature (20 C to 25 C), with permitted excursions up to 30 C. The medication must be kept in its original container and stored in a dry place protected from moisture and light. It is mandatory that the tablets are kept from freezing and that the container remains tightly closed to maintain product integrity.

Child-Safety and Disposal

Storage regulations require the medicine to be kept out of the sight and reach of children at all times. Disposal of any unused or expired Selexid must be performed in accordance with local regulations. Official guidance directs patients not to discard the medicine in wastewater or household trash, advising instead to consult a pharmacist or utilize a drug take-back program.